Dr. Martin Pfister

Principal / Authorized Signatory

Dr. Martin Pfister

Principal / Authorized Signatory

Dr. Martin Pfister studied medicine and pharmacy at the University of Greifswald and New York University and received his doctorate in immunology. He worked in various academic laboratories. Since 2000 he has been active in the start-up scene. He took over management positions and is co-founder of two successful companies in the fields of diagnostics & health services. In 2010 he transferred to the HTGF on the investor side. With his long-standing experience in drug development/gene therapy and medical technology/diagnostics, he is a valued sparring partner for portfolio companies in the fields of biotechnology and healthcare. He also holds several advisory board positions with portfolio companies.

Contact

Telefon:
+49 – (0)228 – 82300 – 123

Portfolio

Posts & mentions

Blog
Blog
5. October 2021

Life Science Pitch Day: Real entrepreneurs, real innovation, real added value

It was a special moment when CureVac founder Ingmar Hoerr shared his business story at the Life Science Pitch Day. More than 30 start-ups, investors, and scientists took part in the event at the end of September, which was organised by High-Tech Gründerfonds (HTGF) together with partners Bayer, Boehringer Ingelheim and the Innovation and Start-Up Center Biotechnology (IZB). We spoke to the event organisers at HTGF: Dr. Caroline Fichtner and Dr. Martin Pfister, both HTGF Principals, touched
 
Press
25. August 2021

Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion Hanover, Germany, August 25, 2021 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, announced today the closing of a €64 million ($76 million) Series B financing round. The round was led by Inkef Capital, supported by fello
 
Press
2. August 2021

Successful exit for High-Tech Gründerfonds – HTGF fund investor Evonik acquires biotech company JeNaCell

Acquisition of JeNaCell expands Evonik’s portfolio of biomaterials used in medical technologyJeNaCell to realize full potential of its innovative technology and further expand its technology portfolio with Evonik’s supportHigh-Tech Gründerfonds (HTGF) financed the seed round in 2012 together with the Foundation for Technology, Innovation and Research Thuringia (STIFT)bm|t acquired stake in JeNaCell in 2015 together with Sparkasse Jena-Saale-Holzland and HTGF fund investor Evonik Venture